Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies

Guadecitabine (SGI‐110) is a novel next‐generation hypomethylating agent (HMA) administered as s.c. injection with extended decitabine exposure. Dose/exposure‐response analyses of longitudinal measures of long interspersed nucleotide element‐1 (LINE‐1) methylation and absolute neutrophil counts (ANC...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Cong, Goggin, Timothy K., Su, Xiang‐Yao, Taverna, Pietro, Oganesian, Aram, Lowder, James N., Azab, Mohammad, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658282/
https://www.ncbi.nlm.nih.gov/pubmed/28960845
http://dx.doi.org/10.1002/psp4.12248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658282/
https://www.ncbi.nlm.nih.gov/pubmed/28960845
http://dx.doi.org/10.1002/psp4.12248

Ejemplares similares